An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

Stopped DLBCL and FL cohorts met the pre-specified futility criteria and will not proceed. The MCL cohort was terminated due to slow recruitment and aggressive disease.

Conditions

• Lymphoma, Mantle-Cell
• Lymphoma, Large B-Cell, Diffuse
• Lymphoma, Follicular

Interventions

• DRUG: Daratumumab

Sponsor

Janssen Research & Development, LLC